Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521659

SCHEMBL1521659

SCHEMBL1521659

CNc1cc2c(cn1)CN(c1cc(NC(=O)Nc3cc(C(C)(C)C)co3)c(F)cc1C)C(=O)N2C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 9/20 0.37
▸ RAF1 P04049 8/20 0.37
▸ KDR P35968 7/20 0.37
▸ KRAS P01116 6/20 0.37
▸ MAP2K2 P36507 5/20 0.37
▸ MAP2K1 Q02750 5/20 0.37
▸ ARAF P10398 1/20 0.35
▸ TNK2 Q07912 7/20 0.33
▸ MAP4K2 Q12851 7/20 0.33
▸ ABL1 P00519 4/20 0.33
▸ BMX P51813 4/20 0.33
▸ LCK P06239 1/20 0.33
▸ FES P07332 1/20 0.33
▸ RET P07949 1/20 0.33
▸ PDGFRB P09619 1/20 0.33
▸ KIT P10721 1/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ PDGFRA P16234 1/20 0.33
▸ FLT1 P17948 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521554 0.87 BRAF (0.48) BRAFRAF1KDRKRASMAP2K2
SCHEMBL1521960 0.87 BRAF (0.37) BRAFRAF1KDRKRASMAP2K2
SCHEMBL1521631 0.85 RAF1 (0.36) BRAFRAF1KDRKRASMAP2K2
SCHEMBL1521888 0.85 RAB9A (0.45) BRAFRAF1RET
SCHEMBL1521988 0.84 BRAF (0.46) BRAFRAF1KDRKRASMAP2K2
SCHEMBL1521957 0.83 BRAF (0.37) BRAFRAF1KDRKRASMAP2K2
SCHEMBL1521647 0.83 RAF1 (0.37) BRAFRAF1KDRKRASMAP2K2
SCHEMBL1521619 0.83 MAPK14 (0.44) BRAFRAF1KDRKRASMAP2K2
SCHEMBL1521766 0.83 TNK2 (0.42) BRAFKDRTNK2MAP4K2ABL1
SCHEMBL1521616 0.83 BRAF (0.37) BRAFRAF1KDRKRASMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.